Entities / Company
IceCure Medical.
Company
- Reports this week
- 0
- Active events
- 0
- Connections
- 29
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
One to three months ago
Gone quiet
No new reports in 90+ days-
IceCure Medical reported financial data and was listed on the Nasdaq electronic stock exchange.Some support2 reports
-
The FDA authorized IceCure Medical's ProSense system for specific indications.Some support1 report
-
IceCure Medical listed its shares on the Nasdaq stock exchange today.Some support1 report
-
Trump pledged to unleash American oil and gas production, involving IceCure Medical.Some support1 report
-
IceCure Medical secured a bridge loan and gained a new largest shareholder, Epoch Partner Investments Limited.Speculative1 report
-
IceCure Medical signed an exclusive distribution agreement with Terumo on July 3, 2025.Speculative1 report
-
IceCure Medical is undergoing a rights offering where Broadridge Corporate Issuer Solutions, LLC is serving as the Subscription Agent and Information Agent.Some support1 report
-
IceCure Medical began marketing its technologies in India, alongside markets in Israel, the US, and Japan.Some support2 reports
-
IceCure Medical is expanding its ProSense technology adoption in Europe while seeking FDA authorization for a breast cancer treatment and planning North American commercialization.Some support2 reports1 development inside
-
ProSense received FDA clearance and approval following a study conducted in Nîmes, France.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around IceCure Medical this week
News at the entities that move IceCure Medical most-
FDA StructuralGeneric medicine services are seeking approval for launch from the FDA.Moves IceCure Medical
-
Nasdaq StructuralApple Inc. stock is traded on Nasdaq, and Jefferies Financial Group restated a hold rating on the company.Moves IceCure Medical
-
Securities and Exchange Commission StructuralBlackRock, the manager of the iShares Core MSCI EAFE ETF, has made required filings with the Securities and Exchange Commission regarding institutional holdings.Moves IceCure Medical
-
Europe Shared contextThe European Central Bank is forced to raise interest rates due to energy price shocks from the Iran war and an influx of Chinese exports.Moves IceCure Medical
-
Straumann Shared contextMarketBeat reports on average recommendation of Moderate Buy for Straumann, while Citigroup restated a sell rating and Morgan Stanley reaffirmed an underweight rating.Moves IceCure Medical
-
MarketBeat Mentioned togetherMarketBeat aggregates data on IDT Corporation stock performance.Moves IceCure Medical
Connections
The 6 strongest of 29, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
IceCure Medical seeks and receives marketing authorization from the FDA for its medical devices.
-
Nasdaq Structural
IceCure Medical is formally listed on the Nasdaq stock exchange, establishing a market dependency for its operations.
-
Securities and Exchange Commission Structural
IceCure Medical is subject to formal regulatory reporting requirements mandated by the Securities and Exchange Commission.
-
Europe Shared context
IceCure Medical markets and increases sales adoption within the European market.
-
Straumann Shared context
Both companies are mentioned as healthcare entities facing market scrutiny.
-
MarketBeat Mentioned together
MarketBeat features IceCure Medical as a company within its stock screening platform.
History
Events by the month they beganAugust 2026
1 eventJune 2026
10 events- IceCure Medical reported financial data and was listed on the Nasdaq electronic stock exchange.
- The FDA authorized IceCure Medical's ProSense system for specific indications.
- IceCure Medical listed its shares on the Nasdaq stock exchange today.
- Trump pledged to unleash American oil and gas production, involving IceCure Medical.
- IceCure Medical secured a bridge loan and gained a new largest shareholder, Epoch Partner Investments Limited.
- IceCure Medical signed an exclusive distribution agreement with Terumo on July 3, 2025.
- IceCure Medical is undergoing a rights offering where Broadridge Corporate Issuer Solutions, LLC is serving as the Subscription Agent and Information Agent.
- IceCure Medical began marketing its technologies in India, alongside markets in Israel, the US, and Japan.
- IceCure Medical is expanding its ProSense technology adoption in Europe while seeking FDA authorization for a breast cancer treatment and planning North American commercialization.
- ProSense received FDA clearance and approval following a study conducted in Nîmes, France.